Thermo Fisher Scientific Inc. (NYSE:TMO) EVP Gianluca Pettiti Sells 300 Shares

Thermo Fisher Scientific Inc. (NYSE:TMO) EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the transaction, the executive vice president now owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded down $3.02 during trading on Monday, hitting $604.12. The stock had a trading volume of 1,228,281 shares, compared to its average volume of 1,564,947. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $614.65. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The stock’s 50 day moving average is $563.01 and its two-hundred day moving average is $565.97. The stock has a market cap of $230.60 billion, a price-to-earnings ratio of 38.75, a price-to-earnings-growth ratio of 2.83 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business’s quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.15 earnings per share. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Analysts Set New Price Targets

TMO has been the subject of a number of recent research reports. JPMorgan Chase & Co. increased their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Stifel Nicolaus boosted their target price on Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research report on Thursday. Raymond James boosted their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research report on Thursday. Barclays decreased their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research report on Friday, June 28th. Finally, TD Cowen boosted their target price on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research report on Thursday. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $618.94.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of institutional investors and hedge funds have recently made changes to their positions in TMO. IFG Advisory LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $220,000. Blue Trust Inc. increased its stake in Thermo Fisher Scientific by 6.0% in the fourth quarter. Blue Trust Inc. now owns 851 shares of the medical research company’s stock valued at $430,000 after acquiring an additional 48 shares during the last quarter. Opal Wealth Advisors LLC increased its stake in Thermo Fisher Scientific by 5.7% in the fourth quarter. Opal Wealth Advisors LLC now owns 804 shares of the medical research company’s stock valued at $427,000 after acquiring an additional 43 shares during the last quarter. Bensler LLC increased its stake in Thermo Fisher Scientific by 15.5% in the fourth quarter. Bensler LLC now owns 6,910 shares of the medical research company’s stock valued at $3,668,000 after acquiring an additional 928 shares during the last quarter. Finally, Palumbo Wealth Management LLC increased its stake in Thermo Fisher Scientific by 10.9% in the fourth quarter. Palumbo Wealth Management LLC now owns 2,782 shares of the medical research company’s stock valued at $1,477,000 after acquiring an additional 274 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.